Table 2. Laboratory findings of patients in the present cohort.
| Patient No. | WBC (×109/L) | Neutrophil (×109/L) | Platelet (×109/L) | ALT (U/L) | AST (U/L) | Tbil (mmol/L) | ESR (mm/h) | CRP (mg/L) | PT (s) | aPTT (s) | Lupus anticoagulant | Anti-cardiolipin IgM (U/mL) | Anti-cardiolipin IgG (U/mL) | Anti-MPO-IgG (RU/mL) | Anti-PR3-IgG (RU/mL) | RF (U/mL) | Brucella Ab | Diagnostic test for Q fever |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10.9 | 7.9 | 366 | 154 | 42 | 15.4 | 57 | 86 | 14.2 | 54 | Detected | 213 | 84.4 | 26.1 | 46.2 | 17 | Negative | CF: phase II 1:640 IFA IgM: phase II 1:800 |
| 2 | 4.6 | 3 | 68 | 107.5 | 100.7 | 53.1 | 17 | 179.5 | 14.4 | 39.4 | Not done | Not done | Not done | Not done | Not done | Not done | Negative | NGS 211 sequences detected |
| 3 | 5.5 | 4.2 | 114 | 46.6 | 30.9 | 15.2 | 17 | 54 | 16.7 | 36.1 | Not done | <2 | <2 | 2.05 | <2 | Not done | Negative | NGS 1021 sequences detected |
| 4 | 5.38 | 4.16 | 196 | 110.6 | 51.9 | 14 | 29 | 68.61 | 14 | 45 | Not done | Not done | Not done | 5.45 | 3.01 | Not done | Not done | Nested real-time PCR positive |
| 5 | 3.75 | 2.87 | 103 | 124.6 | 139 | 10.7 | 40 | 98.57 | 13.7 | 46.3 | Not done | Not done | Not done | Not done | Not done | 8.6 | Not done | Nested real-time PCR positive |
| 6 | 7 | 4.6 | 94 | 11.1 | 25 | 12.7 | 33 | 32 | 13.7 | 49.8 | Detected | 7.89 | 3.67 | <2 | 4.71 | 43.9 | Not done | IFA IgM: phase I > 1:8192, phase II 1:512 |
| 7 | 8.54 | 5.12 | 178 | 86.7 | 56.4 | 26.4 | 51 | 122.91 | 16.8 | 51.9 | Detected | > 800 | > 800 | 76.3 | > 800 | 21.1 | Negative | Nested real-time PCR positive |
| 8 | 6.64 | 4.91 | 220 | 138.4 | 95 | 30.9 | 20 | 89.05 | 14.4 | 45.9 | Not detected | Negative | Negative | Not done | Not done | Not done | Negative | Nested real-time PCR positive |
| 9 | 19 | 15.3 | 290 | 152.5 | 88 | 16.5 | 22 | 124.9 | 14.9 | 60.9 | Detected | 88.2 | >480 | 10.9 | 25.8 | 18.9 | Not done | IFA IgM: phase I 1:1024, phase II 1:1024 |
| 10 | 3.5 | 2.3 | 137 | 76.7 | 53.4 | 7.4 | 5 | 0.45 | 12.4 | 33.9 | Not detected | Negative | Negative | Not done | Not done | 48.1 | Negative | IFA IgM: phase I 1:128, phase II 1:64 |
| 11 | 5.72 | 4.55 | 158 | 33 | 29.5 | 5 | 28 | 12.1 | 13.6 | 36.6 | Not detected | Negative | Negative | Not done | Not done | 8.8 | Negative | IFA IgM: phase I negative, phase II 1:64 |
| 12 | 13.1 | 11.2 | 281 | 98.8 | 75.9 | 26.9 | 111 | 219.2 | 15.5 | 82.3 | Detected | 11.3 | 99.4 | 11.8 | 35.7 | 12.1 | Negative | IFA IgM: phase I 1:2048, phase II 1:8192 |
| 13 | 6.5 | 3.4 | 410 | 52.4 | 42.1 | 5.2 | 7 | 40.7 | 12.5 | 41.1 | Not done | <2 | <2 | <2 | 2.07 | N/A | 1:200 | IFA IgM: phase I 1:128; phase II 1:16 |
| 14 | 3.3 | 2.1 | 151 | 144.8 | 167.9 | 5.3 | Not done | 143.6 | 12.5 | 55.9 | Detected | 293.2 | 34.8 | 4.98 | 16.6 | 10.5 | Negative | IFA IgM: phase I and II not detected, nested real-time PCR positive |
Abbreviation: PCR: polymerase chain reaction; NGS: next-generation sequencing; IFA: immunofluorescence assay; ALT: alanine transaminase; AST: aspartate transaminase; Tbil: total bilirubin; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PT: prothrombin time; aPTT: activated partial thromboplastin time; anti-MPO-IgG: anti-myeloperoxidase-IgG; anti-PR3-IgG: anti-proteinase 3-IgG; RF, rheumatoid factor.